RE:Q4 2023 reports lower fully diluted shares vs Q3 2023ONCY is a LATE STAGE Biotech company that has addressed manufacturing over the course of 2023 and is now going into Phase 3 registration studies, regulatory approval, and the potential near-term commercialization of pelareorep. While early-stage biotechs focus on developing and testing their products, late-stage biotechs shift their focus to manufacturing, regulatory approval, and commercialization.
As reported at the beginning of this year, by Daniel Chancellor, Director of Thought Leadership for Evaluate (a Norstella company), most Big Pharma acquisitions are focused on late- or commercial-stage biotech companies with complementary product portfolios with the acquiring organization, which ONCY has demonstrated through its clinical development of pelareorep.
“Wider macro environment suggests that M&A levels should continue to pick up,” predicted Chancellor.
“It's an exciting time, and we're bullish on 2024. Look out for a lot of activity that we can't even probably predict right now,”
https://lifesciencesintelligence.com/features/understanding-the-value-of-mergers-and-acquisitions-in-life-sciences